Research programme: allergic rhinitis therapeutics - Chiesi USA
Alternative Names: CRTX 058; CRTX 070Latest Information Update: 29 Mar 2012
Price :
$50 *
At a glance
- Originator Cornerstone Therapeutics
- Class
- Mechanism of Action Cholinergic receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic rhinitis
Most Recent Events
- 31 Dec 2011 Discontinued - Preclinical for Allergic rhinitis in USA (unspecified route)